Epidemiology, treatment patterns, and disease burden of cytomegalovirus in hematopoietic cell transplant recipients in selected countries outside of Europe and North America: A systematic review.
cytomegalovirus
disease burden
emerging markets
epidemiology
hematopoietic cell transplantation
systematic review
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
12
05
2023
received:
13
03
2023
accepted:
19
05
2023
medline:
15
8
2023
pubmed:
8
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
Cytomegalovirus (CMV) disease impacts morbidity and mortality in hematopoietic cell transplant (HCT) recipients. This systematic review summarized data on the epidemiology, management, and burden of CMV post-HCT outside of Europe and North America. The MEDLINE, Embase, and Cochrane databases were searched for observational studies and treatment guidelines in HCT recipients across 15 selected countries from Asia-Pacific, Latin America, and Middle East (search period: 1 January 2011-17 September 2021). Outcomes included incidence of CMV infection/disease, recurrence, risk factors, CMV-related mortality, treatments, refractory, resistant CMV, and burden. Of 2708 references identified, 68 were eligible (67 studies and one guideline; 45/67 studies specific to adult allogeneic HCT recipients). The rates of CMV infection and disease within 1 year of allogeneic HCT were 24.9%-61.2% (23 studies) and 2.9%-15.7% (10 studies), respectively. Recurrence occurred in 19.8%-37.9% of cases (11 studies). Up to 10% of HCT recipients died of CMV-related causes. In all countries, first-line treatment for CMV infection/disease involved intravenous ganciclovir or valganciclovir. Conventional treatments were associated with serious adverse events such as myelosuppression (10.0%) or neutropenia only (30.0%, 39.8%) and nephrotoxicity (11.0%) (three studies), frequently leading to treatment discontinuation (up to 13.6%). Refractory CMV was reported in 2.9%, 13.0%, and 28.9% of treated patients (three studies) with resistant CMV diagnosed in 0%-10% of recipients (five studies). Patient-reported outcomes and economic data were scarce. The incidence of CMV infection and disease post-HCT is high outside of North America and Europe. CMV resistance and toxicity highlight a major unmet need with current conventional treatments.
Sections du résumé
BACKGROUND
BACKGROUND
Cytomegalovirus (CMV) disease impacts morbidity and mortality in hematopoietic cell transplant (HCT) recipients. This systematic review summarized data on the epidemiology, management, and burden of CMV post-HCT outside of Europe and North America.
METHODS
METHODS
The MEDLINE, Embase, and Cochrane databases were searched for observational studies and treatment guidelines in HCT recipients across 15 selected countries from Asia-Pacific, Latin America, and Middle East (search period: 1 January 2011-17 September 2021). Outcomes included incidence of CMV infection/disease, recurrence, risk factors, CMV-related mortality, treatments, refractory, resistant CMV, and burden.
RESULTS
RESULTS
Of 2708 references identified, 68 were eligible (67 studies and one guideline; 45/67 studies specific to adult allogeneic HCT recipients). The rates of CMV infection and disease within 1 year of allogeneic HCT were 24.9%-61.2% (23 studies) and 2.9%-15.7% (10 studies), respectively. Recurrence occurred in 19.8%-37.9% of cases (11 studies). Up to 10% of HCT recipients died of CMV-related causes. In all countries, first-line treatment for CMV infection/disease involved intravenous ganciclovir or valganciclovir. Conventional treatments were associated with serious adverse events such as myelosuppression (10.0%) or neutropenia only (30.0%, 39.8%) and nephrotoxicity (11.0%) (three studies), frequently leading to treatment discontinuation (up to 13.6%). Refractory CMV was reported in 2.9%, 13.0%, and 28.9% of treated patients (three studies) with resistant CMV diagnosed in 0%-10% of recipients (five studies). Patient-reported outcomes and economic data were scarce.
CONCLUSION
CONCLUSIONS
The incidence of CMV infection and disease post-HCT is high outside of North America and Europe. CMV resistance and toxicity highlight a major unmet need with current conventional treatments.
Types de publication
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14083Subventions
Organisme : Takeda Pharmaceuticals International AG-Singapore Branch
Informations de copyright
© 2023 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC.
Références
Bhat V, Joshi A, Sarode R, Chavan P. Cytomegalovirus infection in the bone marrow transplant patient. World J Transplant. 2015;4:287-291. doi:10.5500/wjt.v5.i4.287
Zuhair MS. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis. Rev Med Virol. 2019;29(3):e2034. doi:10.1002/rmv.2034
de la Camara R. CMV in hematopoietic stem cell transplantation. Mediterr J Hematol Infect Dis. 2016;1:e2016031. doi:10.4084/mjhid.2016.031
Grigoleit G, Kapp M, Einsele H. Indirect effects of cytomegalovirus infection. Eur Haematol. 2009;3(1):41-44. doi:10.17925/EOH.2009.03.1.41
Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427-2438. doi:10.1182/blood-2015-11-679639
Dioverti MV, Razonable RR. Cytomegalovirus. Microbiol Spectr. 2016;4(4):4. doi:10.1128/microbiolspec.DMIH2-0022-2015
Marty FM, Rubin RH. The prevention of infection post-transplant: the role of prophylaxis, preemptive and empiric therapy. Transpl Int. 2006;19(1):2-11. doi:10.1111/j.1432-2277.2005.00218.x
Cho SY, Lee DG, Kim HJ. Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy. Int J Mol Sci. 2019;20(11):e2666. doi:10.3390/ijms20112666
Morris D. Adverse effects and drug interactions of clinical importance with antiviral. Drug Safety. 1994;10(4):281-291. doi:10.2165/00002018-199410040-00002
Limaye A, Babu T, Boeckh M. Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation. Clin Microbiol Rev. 2021;34(1):e00043-19. doi:10.1128/CMR.00043-19
Gratwohl A, Baldomero H, Aljurf M, et al. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010;303(16):1617-1624. doi:10.1001/jama.2010.491
Page M, McKenzie J, Bossuyt P, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;1:1-11. doi:10.1136/bmj.n71
World Health Organization. Global Index Medicus. World Health Organization. 2021. Retrieved July 5, 2021. https://www.globalindexmedicus.net/
Johanna Briggs Institute. Critical Appraisal Tools. Johanna Briggs Institute. Retrieved November 2, 2022. http://joannabriggs.org/research/critical-appraisal-tools.html
Yong M, Shigle T, Ki YJ, Carpenter P, Chemaly R, Papanicolaou G. American Society for Transplantation and Cellular Therapy Series: #4-cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. Transplant Cell Ther. 2021;27(12):957-967. doi:10.1016/j.jtct.2021.09.010
Yu GP, Yin Z, Fan Z, et al. The efficacy and safety of cidofovir in salvage therapy for CMV infection in the patients with haploid hematopoietic stem cell transplantation. Blood. 2019;134(suppl 1):5659. doi:10.1182/blood-2019-126705
Han S, Yoo S, Do Han K, La Y, Kwon D, Lee K. The incidence and effect of cytomegalovirus disease on mortality in transplant recipients and general population: real-world nationwide cohort data. Int J Med Sci. 2021;18(14):3333-3341. doi:10.7150/ijms.62621
Diaz L, Rosales J, Rosso F, et al. Cytomegalovirus disease in patients with hematopoietic stem cell transplantation, experience over 8 years. Hematol Transfus Cell Ther. 2020;42:18-24. doi:10.1016/j.htct.2018.10.004
Gao XN, Lin J, Wang LJ, et al. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies. Ann Hematol. 2020;99(8):1883-1893. doi:10.1007/s00277-020-04156-6
Lopez M, Pedraza E, Figueroa J, et al. Strategy for cytomegalovirus reactivation prevention with ganciclovir and high dose of valacyclovir in allogeneic stem cell transplantation (Abstract 4076). ECCMID Abstract Book. 2020. p. 1951. Accessed May 23, 2023. https://www.escmid.org/guidelines_publications/eccmid_2020_abstract_book/
Devasia AJ, Mammen S, Korula A, et al. Low incidence of cytomegalo virus infection following allogeneic hematopoietic stem cell transplantation despite a high seroprevalence. Indian J Hematol Blood Transfus. 2018;34(4):363-342. doi:10.1007/s12288-018-0960-y
Kaya AH, Tekgunduz E, Akpinar S, et al. Is cytomegalovirus surveillance necessary for patients with low reactivation risk in an autologous hematopoietic cell transplantation setting? Transplant Proc. 2017;49(8):1911-1915. doi:10.1016/j.transproceed.2017.05.007
Laberko A, Bogoyavlenskaya A, Shelikhova L. Risk factors for and the clinical impact of cytomegalovirus and Epstein-Barr virus infections in pediatric recipients of TCR-alpha/beta- and CD19-depleted grafts. Biol Blood Marrow Transplant. 2017;23(1):483-490. doi:10.1016/j.bbmt.2016.12.635
de Oliveira G, Ueda MY, Real JM, et al. Simultaneous quantification of the 8 human herpesviruses in allogeneic hematopoietic stem cell transplantation. Transplantation. 2016;22(5):1371-1376. doi:10.1097/TP.0000000000000986
Liu J, Chang YJ, Yan C, Xu LP, Jiang ZF, Zhang XH. Poor CMV-specific CD8+ T central memory subset recovery at early stage post-HSCT associates with refractory and recurrent CMV reactivation. J Infect. 2016;73(3):261-270. doi:10.1016/j.jinf.2016.04.033
Atay D, Erbey FA. Oral valganciclovir as preemptive therapy for cytomegalovirus reactivation in pediatric hematopoietic stem cell transplant patients. J Pediatr Hematol Oncol. 2015;37(7):543-547. doi:10.1097/MPH.0000000000000397
Liu J, Kong J, Chang YJ, et al. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality. Clin Microbiol Infect. 2015;21(12):1121.e9-1121.e15. doi:10.1016/j.cmi.2015.06.009
Li Y, Gao L, Wang L, et al. Surveillance of CMV infection in allo-HSCT recipients and guidance on preemptive therapy by RQ-PCR. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013;21(1):161-168. doi:10.7534/j.issn.1009-2137.2013.01.033
Yong MK, Ananda-Rajah M, Cameron PU, et al. Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring. Biol Blood Marrow Transplant. 2017;23(11):1961-1967. doi:10.1016/j.bbmt.2017.07.025
Lam S, Boan P, Polistena P, et al. High dose valaciclovir to prevent cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients. Transpl Infect Dis. 2021;23(4):e13633. doi:10.1111/tid.13633
Kim T, Lee Y, Lee S, et al. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy. Korean J Intern Med. 2016;31(5):961-970. doi:10.3904/kjim.2015.079
Cho BS, Yoon JH, Shin SH, et al. Comparison of allogeneic stem cell transplantation from familial-mismatched/haploidentical donors and from unrelated donors in adults with high-risk acute myelogenous leukemia. Biol Blood Marrow Transplant. 2012;18(10):1552-1563. doi:10.1016/j.bbmt.2012.04.008
Jang JE, Kim SJ, Cheong JW, et al. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia. Ann Hematol. 2014;94(2):275-282. doi:10.1007/s00277-014-2190-1
Sharma S, Kumar S, Agrawal N, et al. Cytomegalovirus reactivation following hematopoietic stem cell transplantation. J Infect Dev Ctries. 2013;7(12):1003-1007. doi:10.3855/jidc.2947
Huang H, Liao X, Li C, et al. The incidence of CMV reactivation and CMV diseases in the haplo-identical hematopoietic stem cell transplantation-a single center experience (Abstract 8763). In: 23rd Annual Congress of 2018 APBMT. 2018.
Lin CH, Su YJ, Hsu CY, Wang PN, Teng CJ. Haploidentical allogeneic hematopoietic stem cell transplantation increases the risk of cytomegalovirus infection in adult patients with acute leukemia. Transpl Infect Dis. 2019;21(4):e13096. doi:10.1111/tid.13096
Eren D, Nur S, Fahri S, et al. Cytomegalovirus infection in autologous hematopoietic stem cell transplant patients with hematological diseases: a single center (Poster 547). Bone Marrow Transplant. 2019:145-805.
Sahin DG, Gunduz EK. Cytomegalovirus DNAemia detected with real-time polymerase chain reaction in hematopoietic stem cell transplant patients. Adv Ther. 2013;8:784-791. doi:10.1007/s12325-013-0049-9
Akyol E, Sahin H, Eksi F, et al. The clinical features of cytomegalovirus infection and its effect on hematopoietic stem cell transplantation and effectiveness of antiviral treatment protocols (Poster 499). Bone Marrow Transplant. 2018;53:520.
Meng XY, Fu HX, Zhu XL, et al. Comparison of different cytomegalovirus diseases following haploidentical hematopoietic stem cell transplantation. Ann Hematol. 2020;99:2659-2670. doi:10.1007/s00277-020-04201-4
Min GJ, Kim HJ, Kim TG, et al. Specific donor HLA allotypes as predictors of cytomegalovirus disease risk in acute myeloid leukemia. HLA. 2020;96(4):445-455. doi:10.1111/tan.13966
He J, Chen BA, Ni M, Wu X, Ding JH. Clinical study of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014;22(5):1371-1376. doi:10.7534/j.issn.1009-2137.2014.05.036
Song T, Chen G, Zhang X, et al. Clinical outcomes of allogeneic hematopoietic stem cell transplantation patients with co-activation of cytomegalovirus and Epstein-Barr virus. Zhonghua Yi Xue Za Zhi. 2014;94(40):3135-3139.
Huang J, Lu X, Yan C, et al. Comparative study on clinical features of cytomegalovirus infection after allogenic hematopoietic stem cell transplantation from HLA haploidentical related donors vs HLA-matched sibling donors. Chin J Organ Transplant. 2013;34(12):87-91. doi:10.3760/cma.j.issn.0254-1785.2013.02.006
Guo Z, Chen HR, Liu XD, et al. Clinical analysis of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012;20(4):971-974.
Yang R, Zhang R, Zhang Y, et al. Risk factors analysis for human cytomegalovirus viremia in donor+/recipient+ hematopoietic stem cell transplantation. Lab Med. 2021;51(1):74-79. doi:10.1093/labmed/lmz030
Chen Y, Xu LP, Liu KY, et al. Risk factors for cytomegalovirus DNAemia following haploidentical stem cell transplantation and its association with host hepatitis B virus serostatus. J Clin Virol. 2016;75:10-15. doi:10.1016/j.jcv.2015.12.003
Xuan L, Huang F, Fan Z, et al. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies. J Hematol Oncol. 2012;5(1):1-12. doi:10.1186/1756-8722-5-46
Yamei WU, Yongbin CA, Xiaohong LI, et al. Clinical study on foscarnet prophylaxis and pre-emptive therapy for cytomegalovirus infection in hematopoietic stem cell transplantation. J Leuk Lymph. 2017;26(6):331-335.
Eren D, Nur S, Fahri S, et al. Cytomegalovirus infection in allogeneic hematopoietic stem cell transplant patients with hematological diseases: a single center (Poster 546). Bone Marrow Transplant. 2019:145-805.
Seo E, Choi ES, Kim JH, et al. Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients. PLoS One. 2021;16(2):e0246191. doi:10.1371/journal.pone.0246191
Eun-Sang YI, Yae-Jean KI. Cytomegalovirus infection according to cell source after hematopoietic cell transplantation in pediatric patients. Yonsei Med J. 2012;53(2):393-400. doi:10.3349/ymj.2012.53.2.393
Acar K, Aki SZ, Ozkurt ZN, Bozdayi G, Rota S, Sucak GT. Factors associated with cytomegalovirus reactivation following allogeneic hematopoietic stem cell transplantation: human leukocyte antigens might be among the risk factors. Turk J Hematol. 2014;31(3):276-285. doi:10.4274/Tjh.2013.0244
Kumar M, Roychowdhury M, Kumar J, et al. Cytomegalovirus reactivation and disease amongst patients with allogeneic haematopoietic stem cell transplantation in Eastern India: epidemiology, outcome and healthcare cost. Indian J Med Microbiol. 2018;36(1):49-53. doi:10.4103/ijmm.IJMM_17_269
Al Yazidi LS, Mitchell RP, O'Brien TA, McMullan B. Management and prevention of cytomegalovirus infection in paediatric hematopoietic stem cell transplant (HSCT) recipients: a binational survey. Pediatr Transplant. 2019;23(5):e13458. doi:10.1111/petr.13458
Damlaj M, Khalid F, Alahmari B, et al. Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status. Curr Res Transl Med. 2020;68(3):131-137. doi:10.1016/j.retram.2020.04.005
Tavil B, Azik FM, Bozkaya I, et al. Prophylactic acyclovir and preemptive ganciclovir to prevent cytomegalovirus disease in children after hematopoietic stem cell transplant. Exp Clin Transplant. 2014;12(5):462-468. doi:10.6002/ect.2013.0238
Cao WJ, Wan DM, Li L, et al. Clinical study of cytomegalovirus infection and preemptive therapy after allogenic hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(4):1143-1148. doi:10.7534/j.issn.1009-2137.2016.04.034
Li PH, Lin CH, Lin YH, Chen TC, Hsu CY, Teng CL. Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation. Ther Adv Hematol. 2021;12:1-11. doi:10.1177/2040620721998124
Krishnamoorthi N, Dubashi B, Ganesan N, et al. Clinical course and outcomes of patients with CMV infection post allogeneic stem cell transplant (Poster 744). Blood Cell Therapy. 2020:173.
Lin HC, Han SM, Hwang WL, et al. Cytomegalovirus infection and treatment in allogeneic hematopoietic stem cell transplantation: a retrospective study from a single institution in an endemic area. Turk J Hematol. 2017;34(2):159-166. doi:10.4274/tjh.2016.0225
Wang LL, Mo WJ, Zhang YP, et al. Clinical analysis of CMV infection after allogeneic hematopoietic stem cell transplantation in severe aplastic anemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021;29(3):944-950. doi:10.19746/j.cnki.issn.1009-2137.2021.03.046
Mo XD, Zhao XY, Liu DH, et al. Umbilical cord blood transplantation and unmanipulated haploidentical hematopoietic SCT for pediatric hematologic malignances. Bone Marrow Transplant. 2014;49(8):1070-1075. doi:10.1038/bmt.2014.109
Wu JL, Ma HY, Lu CY, et al. Risk factors and outcomes of cytomegalovirus viremia in pediatric hematopoietic stem cell transplantation patients. J Microbiol Immunol Infect. 2017;50(3):307-313. doi:10.1016/j.jmii.2015.07.011
Kapoor R, Rastogi N, Thakkar D, Chatterjee G, Yadav S. CMV reactivation after haploidentical stem cell transplant posttransplant cyclophosphamide children (Oral 633). Blood Cell Therapy. 2020:103.
Zou BH, Zhang Q, Xu YR, et al. Analysis of risk factors for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(2):551-555. doi:10.7534/j.issn.1009-2137.2016.02.046
Jang JE, Hyun SY, Kim YD, et al. Risk factors for progression from cytomegalovirus viremia to cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(6):881-886. doi:10.1016/j.bbmt.2011.10.037
Park SY, Lee SO, Choi SH, et al. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study. J Antimicrob Chemother. 2012;67(6):1486-1492. doi:10.1093/jac/dks043
Jaing TH, Chang TY, Chen SH, et al. Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation. Medicine. 2019;98(4):e14172. doi:10.1097/MD.0000000000014172
Alsultan M, Siddiqui K, Ayas M, et al. Cytomegalovirus infection among pediatric patients undergoing hematopoietic stem cell transplant in an endemic area-report from a tertiary care center in Saudi Arabia (Poster 438). Bone Marrow Transplant. 2019;54:426-427.
Han Kang S, Won Yoo J, Kyung Seo J, et al. The role of combination prophylaxis in preventing cytomegalovirus (CMV) infection after ex vivo AB T-cell-depleted haploidentical hemaopoietic cell transplant (HHCT) in children (Poster 366). Bone Marrow Transplant. 2020;55(suppl 1):456-457.
Yu U, Huang X, Wen J, et al. Cytomegalovirus infection and the implications of drug resistant mutations in pediatric hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2020;67(S4):e28742. doi:10.1002/pbc.28742
Qiu H, Bao X, Xue S, et al. Clinic risk factors of refractory CMV reactivation following allogeneic aHSCT: a single-center study in China. Bone Marrow Transplant. 2016;51:S206.
Yong M, Raj S, Yeoh Z, Slavin M, Hudson Y, Ritchie D. The long term impact of cytomegalovirus (CMV) viremia on quality of life in allogeneic haematopoietic cell transplant recipients (HCT). Biol Blood Marrow Transplant. 2020;26( supplement3):S359-S360. doi:10.1016/j.bbmt.2019.12.189
Yong MK, Tio SY, Valentine J, et al. The economic and health utilization cost of clinically significant cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. Blood. 2019;134(supplement 1):3437. doi:10.1182/blood-2019-128227
Ljungman P, Boeckh M, Hirsch H, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2016;64(1):87-91. doi:10.1093/cid/ciw668
Bergamasco A, Goyer C, Arredondo-Bisono T, Sen R, Hirji I, Moride Y. Epidemiology of resistant and refractory cytomegalovirus infection following solid organ or haematopoietic stem cell transplant: a systematic review. Bone Marrow Transplant. 2021;56(suppl 1):263-264.
Caliendo A. Overview of Diagnostic Tests for Cytomegalovirus Infection. UpToDate. 2016. Retrieved July 6, 2022. https://www.medilib.ir/uptodate/show/8291#top
Fryer JF, Heath AB, Minor PD. A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology. Biologicals. 2016;44(4):242-251. doi:10.1016/j.biologicals.2016.04.005
Huntley D, Gimenez E, Pascual MJ, et al. Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide. Transpl Infect Dis. 2020;22(1):e13206. doi:10.1111/tid.13206
Reekie J, Helleberg M, Ekenberg C, et al. Absolute lymphocyte count as a predictor of CMV infection and recurrence in HSCT recipients (Poster 1075). Open Forum Infect Dis. 2020;7(suppl 1):S565. doi:10.1093/ofid/ofaa439.1261
Solano C, Vasquez L, Gimenez E, et al. Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. Am J Transplant. 2020;21(1):258-271. doi:10.1111/ajt.16147
Huang Y, Su Y, Kim SJ, Nichols P. Cytomegalovirus infection in allogeneic hematopoietic cell transplantation managed by the preemptive approach: estimating the impact on healthcare resource utilization and outcomes. Biol Blood Marrow Transplant. 2019;25(4):791-799. doi:10.1016/j.bbmt.2018.11.012
Webb B, Harrington R, Schwartz J, et al. The clinical and economic impact of cytomegalovirus infection in recipients of hematopoietic stem cell transplantation. Transpl Infect Dis. 2018;20(5):e12961. doi:10.1111/tid.12961
Sola Aparicio E, Cardenoso L, Lopez Pereira P, et al. Impact of CMV replication in overall survival in allogeneic HSCT recipients. Bone Marrow Transplant. 2019;54:432.
Servais S, Dumontier N, Biard L, et al. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status. Clin Microbiol Infect. 2016;22(3):289.e1-289.e7. doi:10.1016/j.cmi.2015.11.006
Camargo J, Kimble E, Rosa R, et al. Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2018;24(4):806-814. doi:10.1016/j.bbmt.2017.11.038
Tan S, Waggoner J, Pinsky B. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients. J Clin Virol. 2015;69:179-183. doi:10.1016/j.jcv.2015.06.006
Chemaly R, Chou S, Einsele H, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68(8):1420-1426. doi:10.1093/cid/ciy696
Yong MK. Invasive fungal disease and cytomegalovirus infection: is there an association? Curr Opin Infect Dis. 2018;6:481-489. doi:10.1097/QCO.0000000000000502
Beswick J, Shin E, Michelis FV, et al. Incidence and risk factors for nontuberculous mycobacterial infection after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2018;24(2):366-372. doi:10.1016/j.bbmt.2017.09.015
Bueno F, Solano C, Vazquez L, et al. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood SCT: a multicenter study from the Spanish hematopoietic transplantation and cell therapy group. Transpl Infect Dis. 2021;23(4):e13627. doi:10.1111/tid.13627
Goldsmith S, Abid MB, Auletta JJ, et al. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021;137(23):3291-3305. doi:10.1182/blood.2020009362
Lindsay J, Greenwood M, Othman J, et al. Treatment failure cost analysis of cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation. Leuk Lymphoma. 2022;63(9):2254-2256. doi:10.1080/10428194.2022.2064992
Zavras P, Su Y, Fang J, et al. Impact of preemptive therapy for cytomegalovirus on toxicities after allogeneic hematopoietic cell transplantation in clinical practice: a retrospective single-center cohort study. Biol Blood Marrow Transplant. 2020;26(8):1482-1491. doi:10.1016/j.bbmt.2020.03.019
Camargo J, Anderson AD, Rosa R, Kimble E, Komanduri KV, Morris MI. Use of maintenance therapy and incidence of recurrent cytomegalovirus DNAemia among allogeneic hematopoietic cell transplant recipients. Transpl Infect Dis. 2019;21:e13054. doi:10.1111/tid.13054
El Haddad L, Ghantoji SS, Park AK, et al. Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. J Med Virol. 2020;92(1):86-95. doi:10.1002/jmv.25574
Avery R, Silveira FP, Benedict K, et al. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the organ transplant infection prevention and detection study: a multi-year, multicenter prospective cohort study. Transpl Infect Dis. 2018;3:e12877. doi:10.1111/tid.12877
Douglas G, Yong MK, Tio SY, et al. Effective CMV prophylaxis with high-dose valaciclovir in allogeneic hematopoietic stem-cell recipients at a high risk of CMV infection. Transpl Infect Dis. 2023;25(1):e13994. doi:10.1111/tid.13994
Avery R, Alain S, Alexander B, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. 2022;75(4):690-701. doi:10.1093/cid/ciab988
Sassine J, Khawaja F, Shigle TL, et al. Refractory and resistant cytomegalovirus after hematopoietic cell transplant in the letermovir primary prophylaxis era. Clin Infect Dis. 2021;73(8):1346-1354.
Einsele HL. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood. 2020;19:1619-1629. doi:10.1182/blood.2019000956